Global budget: 834 k€
Public funding: 400 k€
Public funders: Cancéropôle CLARA, Grand Lyon
Call for projects: Proof of concept CLARA
Year start: 2008
Completed project (2012-08)
Strategic business area: Human Medicines
Application fields: Oncology, Lung
Technological approaches / Keywords: Biologics
Stage of development at the beginning of the project: Discovery
DRs are trans-membrane proteins that behave like “molecular switches” operated by their ligand (absence of the ligand induces apoptosis). Netrin-1 ligand is over-expressed in 60% of breast tumors and appears to be highly correlated to cancer metastatic potentiality. The therapeutic approach was to titrate the ligand with a drug candidate, to let the DR re-induce a cell death signal.
The aim of the project was to design, produce and optimize such a drug candidate, to determine its pharmacokinetic and pharmacodynamic characteristics and its efficacy in mice models of lung cancer.
-Development of a drug candidate in a context of targeted therapeutic strategy -Use of Netrin-1 expression level as a prognosis marker
